低氧诱导的多氧化物生物降解增强瘤透和抗瘤效果
在PubMed上查看摘要
概括
此摘要是机器生成的。与PEGylated干扰素相比,新的多氧化物药物合物显示出瘤透和疗效的增强. 这项突破为固体瘤提供了更好的治疗方法,
科学领域
- 生物材料科学
- 提供药物
- 癌症学
背景情况
- 基化增强药物循环,但阻碍瘤透.
- 固体瘤需要改善药物输送才能有效治疗.
研究的目的
- 开发一种新的生物可降解聚合物,聚N-氧化物,用于对干扰素α (IFN) 进行特定位点的结合.
- 与PEGASYS相比,评估IFN-多氧化的瘤透率,循环时间和抗瘤功效.
主要方法
- 在现场聚合聚氧化物到干扰素α.
- 在体内对结合物循环半衰期的评估.
- 在患有黑色素瘤的小鼠中评估瘤透和抗瘤功效.
主要成果
- 与PEGASYS相比,IFN-多 (N-氧化物) 结合物的循环半衰期为51小时.
- 与PEGASYS和未修改的IFN相比,结合剂显著增强了瘤透和抗瘤功效.
- 增强的透归因于低氧诱导的多氧化物转化为多氨酸,从而促进吸附介导的转细胞.
结论
- 聚氧化物是长期循环的,在缺氧下可生物降解,并且在瘤药物输送方面优于PEG.
- 作为下一代载体, 它们对固体瘤治疗具有很大的前景.
- 生物可降解聚合物的特定结合提供了一种改善药物输送到瘤的新策略.
相关概念视频
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...

